MC180295
Lintlha tsa Sehlahisoa
Li-tag tsa Sehlahisoa
| Boholo ba Pakete | Ho fumaneha | Theko (USD) |
Lebitso la lik'hemik'hale:
Rel-(4-amino-2-(((2S)-bicyclo[2.2.1]heptan-2-yl)amino)thiazol-5-yl)(2-nitrophenyl)methanone
SMILES Khouto:
O=C(C1=C(N)N=C(N[C@H]2C(C3)CCC3C2)S1)C4=CC=CC=C4[N+]([O-])=O
Khoutu ea InChi:
InChI=1S/C17H18N4O3S/c18-16-15(14(22)11-3-1-2-4-13(11)21(23)24)25-17(20-16)19-12-8- 9-5-6-10(12)7-9/h1-4,9-10,12H,5-8,18H2,(H,19,20)/t9?,10?,12-/m0/s1
InChi Key:
JRNXAQINDCOHGS-CBINBANVSA-N
Keyword:
Sollubility:
Polokelo:
Tlhaloso:
MC180295 ke CDK9 inhibitor e khethang haholo (IC50 = 5 nM). (MC180295 e na le ts'ebetso e pharaletseng ea anti-cancer in vitro mme e sebetsa hantle mefuteng ea mofets'e oa vivo. Ho feta moo, CDK9 inhibition e hlokomelisa ho immune checkpoint inhibitor α-PD-1 in vivo, e etsa hore e be sepheo se setle sa kalafo ea epigenetic ea mofets'e.
Sepheo: CDK9
